Literature DB >> 500822

Isolation and characterization of heparin from human lung.

D D Metcalfe, R A Lewis, J E Silbert, R D Rosenberg, S I Wasserman, K F Austen.   

Abstract

Heparin as measured by azure A metachromasia and anticoagulant activity has been extracted with 1 M NaCl from (35)S-labeled human lung fragments or dispersed human lung cells enriched for mast cells. The (35)S-labeled metachromatic material in the 3 M NaCl eluate from Dowex-1 chromatography of the extract from lung fragments exhibited an average mol wt of 20,000 by Sepharose 4B gel filtration. The (35)S-labeled metachromatic material with the charge characteristics of commercial porcine heparin on DEAE cellulose chromatography was entirely heparin by the criteria of resistance to degradation by chondroitin ABC lyase and complete degradation by purified heparinase. Antithrombin affinity chromatography of purified heparin with an anticoagulant activity of 137 U/mg, revealed that the one-third that was bound and eluted had a 273 U/mg sp act, whereas the unbound activity was 31 U/mg. Thus, the previously observed heterogeneity of commercial porcine heparin for binding to human antithrombin was also observed with human heparin. The mast cell-enriched human lung cell preparations yielded [(35)S]mucopolysaccharides with an average mol wt of 60,000 by Sepharose 4B gel filtration. Approximately 30% of this fraction was degraded by chondroitin ABC lyase, and the residual 70% was degraded by purified heparinase. When the chondroitin ABC lyase-resistant fraction was subjected to alkali degradation the average mol wt was reduced to 20,000. The calculated human lung mast cell heparin content of 2.4-7.8 mug/10(6) cells gave a ratio to histamine on a weight basis similar to that of intact lung fragments, thereby implying that heparin in the lung fragments was largely restricted to the mast cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 500822      PMCID: PMC371305          DOI: 10.1172/JCI109613

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

Review 1.  Biologic actions of heparin.

Authors:  R D Rosenberg
Journal:  Semin Hematol       Date:  1977-10       Impact factor: 3.851

2.  The separation of active and inactive forms of heparin.

Authors:  L H Lam; J E Silbert; R D Rosenberg
Journal:  Biochem Biophys Res Commun       Date:  1976-03-22       Impact factor: 3.575

3.  Separation of mast cells in successive stages of differentiation using programmed gradient sedimentation.

Authors:  T G Pretlow; I M Cassady
Journal:  Am J Pathol       Date:  1970-12       Impact factor: 4.307

4.  Histamine and heparin release from isolated rat mast cells exposed to compound 48-80.

Authors:  S A Slorach
Journal:  Acta Physiol Scand       Date:  1971-05

5.  The heterogeneity of heparins.

Authors:  S E Lasker
Journal:  Fed Proc       Date:  1977-01

6.  Structural studies of heparitin sulfates.

Authors:  A Linker; P Hovingh
Journal:  Biochim Biophys Acta       Date:  1975-04-07

7.  Native heparin from rat peritoneal mast cells.

Authors:  R W Yurt; R W Leid; K F Austen
Journal:  J Biol Chem       Date:  1977-01-25       Impact factor: 5.157

8.  Structure-function relationships of heparin species.

Authors:  R D Rosenberg; G Armand; L Lam
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

9.  Sulfated glycosaminoglycans of guinea pig basophilic leukocytes.

Authors:  N S Orenstein; S J Galli; A M Dvorak; J E Silbert; H F Dvorak
Journal:  J Immunol       Date:  1978-08       Impact factor: 5.422

10.  Release of chemical mediators from partially purified human lung mast cells.

Authors:  N A Paterson; S I Wasserman; J W Said; K F Austen
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

View more
  37 in total

Review 1.  The diverse effects of mast cell mediators.

Authors:  Colleen Hines
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

Review 2.  Biological implications of preformed mast cell mediators.

Authors:  Anders Lundequist; Gunnar Pejler
Journal:  Cell Mol Life Sci       Date:  2010-11-11       Impact factor: 9.261

Review 3.  Leukocyte activation following IgE dependent mechanisms in bronchial asthma.

Authors:  S R Durham
Journal:  Clin Rev Allergy       Date:  1989

Review 4.  Mast cells and mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Blood       Date:  2008-08-15       Impact factor: 22.113

Review 5.  Mast cell proteoglycans.

Authors:  Elin Rönnberg; Fabio R Melo; Gunnar Pejler
Journal:  J Histochem Cytochem       Date:  2012-08-16       Impact factor: 2.479

6.  Glycosaminoglycan metabolism before molecular biology: reminiscences of our early work.

Authors:  Jeremiah E Silbert
Journal:  Glycoconj J       Date:  2009-09-02       Impact factor: 2.916

7.  Release of elastase from purified human lung mast cells and basophils. Identification as a Hageman factor cleaving enzyme.

Authors:  H L Meier; E S Schulman; L W Heck; D MacGlashan; H H Newball; A P Kaplan
Journal:  Inflammation       Date:  1989-06       Impact factor: 4.092

8.  Regulation of human mast cell tryptase. Effects of enzyme concentration, ionic strength and the structure and negative charge density of polysaccharides.

Authors:  S C Alter; D D Metcalfe; T R Bradford; L B Schwartz
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

9.  Generation of leukotriene C4 from a subclass of mast cells differentiated in vitro from mouse bone marrow.

Authors:  E Razin; J M Mencia-Huerta; R A Lewis; E J Corey; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

Review 10.  Mast cells in allergic diseases and mastocytosis.

Authors:  D L Marquardt; S I Wasserman
Journal:  West J Med       Date:  1982-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.